CYP-1020 + Risperidone
Phase 2/3Terminated 0 watching 1 views this week⚡ Active
57
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Schizophrenia
Conditions
Schizophrenia, Cognitive Effect on Schizophrenic Patients
Trial Timeline
May 1, 2011 → Apr 1, 2013
NCT ID
NCT01363349About CYP-1020 + Risperidone
CYP-1020 + Risperidone is a phase 2/3 stage product being developed by BioLineRx for Schizophrenia. The current trial status is terminated. This product is registered under clinical trial identifier NCT01363349. Target conditions include Schizophrenia, Cognitive Effect on Schizophrenic Patients.
Hype Score Breakdown
Clinical
22
Activity
15
Company
2
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01363349 | Phase 2/3 | Terminated |
Competing Products
20 competing products in Schizophrenia